We focus on effective antibody therapies. Find out more about our products ATG-Fresenius® S and Removab®.
Welcome to Neovii Biotech
Whether you are a physician, journalist, patient, investor, future employee, or partner, this website is intended to present the aspects of our biotechnology company that interest you most.
If you cannot find the information you are looking for, do not hesitate to Contact us. We are looking forward to getting to know you and answering your questions about Neovii Biotech.
ESMO 2012: New phase IIIb study confirms the shorter infusion time, efficacy and safety of catumaxomab in malignant ascites
Fresenius Biotech obtains reimbursement approval for Removab® antibody in Belgium
Removab® receives approval for a shorter infusion time in treating malignant ascites – one-year survival rate in Removab®-treated patients is more than four times higher
Fresenius Biotech obtains reimbursement approval for Removab® antibody in Italy
ASCO 2011: Fresenius Biotech presents new data for the trifunctional antibody Removab® − benefit in overall survival of cancer patients demonstrated
Fresenius Biotech’s ATG-Fresenius® S approved in Austria for GVHD prophylaxis in stem cell transplantations
Fresenius Biotech’s ATG-Fresenius® S approved for GVHD prophylaxis in stem cell transplantations in Germany
Fresenius Biotech announces agreement with Swedish Orphan Biovitrum for distribution of Removab®
Removab® (Catumaxomab) wins Galenus-von-Pergamon award
Fresenius Biotech presents new data on trifunctional antibody Removab® at 46th ASCO Annual Meeting in Chicago
Fresenius Biotech launches new corporate website
Removab® receives marketing approval